Latest news and press releases about BridgeBio Pharma, Inc. (BBIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Price
| Price | $66.14 |
| Market Cap | $13.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -5.23 |
| EV / EBITDA | -24.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 31.67% |
| Return on Invested Capital | -61.77% |
| Return on Assets | -57.20% |
| Gross Margin | 93.14% |
| Operating Margin | -78.56% |
| Net Margin | -100.64% |
Related companies: ASND · BMRN · EXEL · IONS · JAZZ · MRNA · RNA
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks